KIN-8741
/ Xoma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 03, 2025
Discovery of KIN-8741, a Highly Selective Type IIb c-Met Kinase Inhibitor with Broad Mutation Coverage and Quality Drug-Like Properties for the Treatment of Cancer.
(PubMed, J Med Chem)
- "Herein, we describe how structure-based drug design (SBDD) directed at optimization of lipophilic efficiency (LipE) enabled the discovery of a highly selective type IIb c-Met inhibitor with quality drug-like properties. Lead compound KIN-8741 exhibits broad potency against acquired resistance mutations and a desirable safety profile that supported the filing and clearance of an IND for the treatment of cancer."
Journal • Oncology • MET
September 18, 2023
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
(GlobeNewswire)
- "Kinnate expects to file an IND application for KIN-8741 with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2023....Kinnate is exploring drug candidates (DC) for a potentially brain-penetrant, selective CDK4 inhibitor and expects to nominate a DC in the fourth quarter of 2023."
IND • Pipeline update • Oncology
April 17, 2023
Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance
(GlobeNewswire)
- "Kinnate Biopharma...announced the addition of two new internally developed next generation development candidates to its targeted oncology pipeline....KIN-7136 is designed to be a next generation brain-penetrant MEK inhibitor for investigation in advanced adult solid tumors, primarily non-small cell lung cancer (NSCLC)...Kinnate expects to enter the clinic with KIN-7136 in the second half of 2023, pending U.S. Food and Drug Administration (FDA) clearance on its investigational new drug (IND) application....KIN-8741 is designed to be a highly selective c-MET inhibitor with broad mutational coverage, including acquired resistance mutations, across a variety of solid tumors in which c-MET is overexpressed, such as NSCLC. Kinnate expects to enter the clinic with KIN-8741 in the first half of 2024, pending FDA clearance on its IND application....The company will deprioritize development for its CDK12 program and evaluate strategic alternatives..."
New trial • Pipeline update • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer
1 to 3
Of
3
Go to page
1